DOCSLIB.ORG

Medicines Formulary

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medicines Formulary MEDICINES FORMULARY Medicines formulary between MCHFT and Primary Care as agreed by the Joint Medicines Management committee Introduction Welcome to the MCHFT Medicines Formulary. The formulary includes medicines that have been approved by the Joint Medicines Management Committee (JMMC) for prescribing within the trust. The purpose of the formulary is to ensure prescribing is evidence based and cost effective. All prescribing within the trust (i.e. inpatient, outpatient and FP10HNC prescribing) must comply with the formulary. This will be monitored on a regular basis. Some drugs may appear in more than one section. The formulary is arranged in sections corresponding to those in the British National Formulary (BNF) as below; GASTRO-INTESTINAL SYSTEM ................................................................................................................ 4 CARDIOVASCULAR SYSTEM .................................................................................................................... 8 RESPIRATORY SYSTEM .......................................................................................................................... 14 CENTRAL NERVOUS SYSTEM ................................................................................................................ 17 INFECTIONS ............................................................................................................................................. 23 ENDOCRINE SYSTEM .............................................................................................................................. 26 OBSTETRICS, GYNAECOLOGY AND URINARY-TRACT DISORDERS .................................................. 31 MALIGNANT DISEASE AND IMMUNOSUPPRESSION ............................................................................ 34 NUTRITION AND BLOOD ......................................................................................................................... 39 MUSCULOSKELETAL AND JOINT DISORDERS ..................................................................................... 43 EYE ............................................................................................................................................................ 45 EAR, NOSE AND OROPHARYNX ............................................................................................................. 49 SKIN ........................................................................................................................................................... 50 IMMUNOLOGICAL PRODUCTS AND VACCINES .................................................................................... 55 ANAESTHESIA .......................................................................................................................................... 56 Page 1 of 57 Operation of the Formulary Items available for general prescribing and restricted items are identified according to the following colour coding; Item Colour Code Items available for general prescribing Second line/use on specialist advice Consultant prescribing only Where a drug is the subject of a NICE Technology Appraisal (TA) the reference number of the guidance is given below the drug entry. Where a drug has been approved by the Joint Medicines Management Committee (JMMC) the month and year of the relevant meeting is also listed below the drug entry. NICE guidance can be found at; Technology Appraisals (TA) http://www.nice.org.uk/guidance/published?type=ta Clinical Guidelines (CG) http://www.nice.org.uk/guidance/published?type=cg MHRA Alerts and recalls on drugs and medical devices https://www.gov.uk/drug-device-alerts Patients taking a non-formulary drug on admission Treatment with a non-formulary drug may be continued in this instance; however it must be borne in mind that there may be a delay in obtaining a non-formulary drug. Additions to the formulary The addition of a new drug or preparation will only be made after approval by the Joint Medicines Management Committee. To request an addition to the formulary a New Product Request (NPR) form must be submitted to the JMMC. This form can be found under Frequently Used Forms- Medicines Management on the trust intranet. New non-formulary drugs required for an individual patient in exceptional circumstances Such an application for a “one-off” use may be made to the chairperson of the JMMC, if the drug is required before the next JMMC meeting. Page 2 of 57 Updates Date BNF Update Details Section See formulary entry for full details September 3.4.2 Omalizumab 2015 8.2.3 Obinutuzumab 8.2.3 Ofatumumab 9.4.1 Locasol 8.1.5 Nintedanib October 1.5.3 Vedolizumab 2015 2.8.2 Edoxaban 1.6.7 Naloxagol 10.1.3 Infliximab biosimilar November 6.1.6 Freestyle Optium beta-ketone testing strip 2015 5.1.7 Fosfomycin injection 5.1.1.2 Temocillin Injection 5.2.3 Amphotericin suspension December 6.1.2 Dulaglutide 2015 2.5.5 Entresto January 11.4.2 Ciclosporin eye drops 1mg/mL 2016 6.5.2 Tolvaptan 8.1.5 Idelalisib February 4.3.4 Vortioxetine 2016 9.2.2.1 Sodium Chloride 0.9% Glucose 5% KCl 20mmol infusion 5.3.3.2 Ledipasvir – sofosbuvir 5.3.3.2 Daclatasvir 5.3.3.2 Ombitasvir – paritaprevir - ritonavir March 5.4.1 Artesunate 2016 6.1.6 Glucomen LX ketone monitoring strips 8.1.5 Bortezomib 13.5.3 Sirolimus 0.1% in WSP 10.1.3 Abatacept, adalimumab, etanercept and tocilizumab for juvenile idiopathic arthritis 8.1.5 Erlotinib April 2016 6.1.1.1 Insulin Lispro 200units/mL 6.1.1.2 Insulin Glargine 300units/mL 6.1.1.2 Insulin Lantus - Abasaglar 8.1.5 Ruxolitinib 5.3.3.1 Entecavir 2.9 Aspirin suppositories – unlicensed 3.11 Nintedanib 8.1.5 Panobinostat May 2016 8.3.4 Abiraterone 2.12 Ezetimibe 4.7.2 Oxycodone PCA 2.5.5.2 Sacubitril/Valsartan 6.4.1 Ulipristil 5mg June 2016 13.10.01 Octenilin wound gel Page 3 of 57 1 Gastro-Intestinal System 1.1 Dyspepsia and gastro-oesophogeal reflux-disease 1.1.1 Antacids and simeticone MAGNESIUM TRISILICATE MIXTURE SIMETICONE LIQUID SODIUM CITRATE ORAL SOLUTION - OXETACAINE ANTACID SUSPENSION - On Christies recommendation 1.1.2 Compound alginates and proprietary indigestion preparations GAVISCON® ADVANCE SF SUSPENSION and TABLETS GAVISCON® INFANT DUAL-SACHETS GAVISON® SF LIQUID (Aniseed) 1.2 Antispasmodics and other drugs altering gut motility Antimuscarinics DICYCLOVERINE LIQUID and TABLETS HYOSCINE BUTYLBROMIDE INJECTION and TABLETS KOLANTICON® GEL Other antispasmodics ALVERINE CITRATE CAPSULES MEBERINE 135mg TABLETS PEPPERMIINT OIL E/C CAPSULES (Mintec®) MEBEVERINE 50mg/5ml LIQUID 1.3 Antisecretory drugs and mucosal protectants 1.3.1 H2 receptor antagonists RANITIDINE INJECTION LIQUID and TABLETS RANITIDINE 150mg EFFERVESCENT TABLETS 1.3.2 Selective antimuscarinics – No products on formulary 1.3.3 Chelates and complexes – No products on formulary 1.3.4 Prostaglandin analogues MISOPROSTOL 200microgram TABLETS 1.3.5 Proton pump inhibitors LANSOPRAZOLE CAPSULES OMEPRAZOLE CAPSULES AND INJECTION PANTOPRAZOLE TABLETS ESOMEPRAZOLE CAPSULES - Restricted for use in severe GORD LANSOPRAZOLE ORODISPERSIBLE TABLETS - For use in patients with swallowing difficulties only OMEPRAZOLE DISPERSIBLE TABLETS - For use in patients with swallowing difficulties only RABEPRAZOLE TABLETS 1.4 Acute Diarrhoea 1.4.1 Adsorbents and bulk-forming drugs – No products on formulary 1.4.2 Antimotility drugs LOPERAMIDE CAPSULES and LIQUID 1.4.3 Enkephalinase inhibitors RACECADOTRIL - JMMC Approved Dec 2012 for treatment of acute diarrhoea in paediatrics 1.5 Chronic bowel disorder Page 4 of 57 1.5.1 Aminosalicylates BALSALAZIDE 750mg CAPSULES MESALAZINE 1g FOAM ENEMA ( Asacol® or Salofalk®) MESALAZINE 500mg SACHETS (Salofalk®) MESALAZINE 1g M/R SACHETS (Pentasa®) MESALAZINE SUPPOSITORIES MESALAZINE E/C; M/R TABLETS (Octasa®) MESALAZINE 500mg M/R TABLETS (Pentasa®) MESALAZINE 250mg E/C TABLETS (Salofalk®) SULFASALAZINE LIQUID, SUPPOSITORIES and TABLETS MESALAZINE 1200mg M/R TABLETS (Mezavant®) 1.5.2 Corticosteroids PREDNISOLONE 20mg FOAM AEROSOL PREDNISOLONE 20mg in 100ml ENEMA PREDNISOLONE 5mg SUPPOSITORIES BUDESONIDE 3mg E/C CAPSULES (Budenofalk®) BUDESONIDE 3mg M/R CAPSULES (Entocort®) 1.5.3 Drugs affecting the immune response AZATHIOPRINE MERCAPTOPURINE METHOTREXATE Cytokine modulators ADALIMUMAB INJECTION - NICE guidance TA187 – Crohn’s disease JMMC Approved Jun 2008 NICE guidance TA329 (includes review of TA140 and TA262) – treatment of moderate to severe ulcerative colitis after failure of conventional therapy JMMC Approved May 2015 INFLIXIMAB - NICE guidance TA163 – Ulcerative colitis (acute exacerbations) NICE guidance TA187 – Crohn’s disease NICE guidance TA329 (includes review of TA140 and TA262) – treatment of moderate to severe ulcerative colitis after failure of conventional therapy JMMC Approved May 2015 GOLIMUMAB- NICE guidance TA329 (includes review of TA140 and TA262) – treatment of moderate to severe ulcerative colitis after failure of conventional therapy JMMC Approved May 2015 VEDOLIZUMAB- NICE guidance TA342 – Moderate to severe active ulcerative colitis JMMC Approved Aug 2015 NICE guidance TA352 – Moderate to severe active Crohn’s disease after prior therapy JMMC Approved Oct 2015 1.5.4 Food allergy - No products on formulary 1.6 Laxatives 1.6.1 Bulk-forming laxatives ISPAGHULA HUSK SACHETS (Fybogel® orange) METHYLCELLULOSE 500mg TABLETS NOMACOL® PLUS SACHETS NORMACOL® SACHETS 1.6.2 Stimulant laxatives BISACODYL SUPPOSITORIES and TABLETS DOCUSATE SODIUM CAPSULES and LIQUID GLYCEROL SUPPOSITORIES SENNA LIQUID and TABLETS CO-DANTHRAMER CAPSULES and LIQUID - Only for constipation
Load more

Recommended publications
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,149,560 B2 Askari Et Al
    USOO9149560B2 (12) United States Patent (10) Patent No.: US 9,149,560 B2 Askari et al. (45) Date of Patent: Oct. 6, 2015 (54) SOLID POLYGLYCOL-BASED 6,149,931 A 11/2000 Schwartz et al. BOCOMPATIBLE PRE-FORMULATION 6,153,211 A 11/2000 Hubbell et al. 6,180,687 B1 1/2001 Hammer et al. 6,207,772 B1 3/2001 Hatsuda et al. (71) Applicant: Medicus Biosciences LLC, San Jose, 6,312,725 B1 1 1/2001 Wallace et al. CA (US) 6,458,889 B1 10/2002 Trollsas et al. 6,475,508 B1 1 1/2002 Schwartz et al. (72) Inventors: Syed H. Askari, San Jose, CA (US); 6,547,714 B1 4/2003 Dailey 6,566,406 B1 5/2003 Pathak et al. Yeon S. Choi, Emeryville, CA (US); 6,605,294 B2 8/2003 Sawhney Paul Yu Jen Wan, Norco, CA (US) 6,624,245 B2 9, 2003 Wallace et al. 6,632.457 B1 10/2003 Sawhney (73) Assignee: Medicus Biosciences LLC, San Jose, 6,703,037 B1 3/2004 Hubbell et al. CA (US) 6,703,378 B1 3/2004 Kunzler et al. 6,818,018 B1 1 1/2004 Sawhney 7,009,343 B2 3/2006 Lim et al. (*) Notice: Subject to any disclaimer, the term of this 7,255,874 B1 8, 2007 Bobo et al. patent is extended or adjusted under 35 7,332,566 B2 2/2008 Pathak et al. U.S.C. 154(b) by 0 days. 7,553,810 B2 6/2009 Gong et al.
    [Show full text]
  • Systematic Review of Tranexamic Acid Adverse Reactions
    arm Ph ac f ov l o i a g n il r a n u c o e J Journal of Pharmacovigilance Calapai et al., J Pharmacovigilance 2015, 3:4 ISSN: 2329-6887 DOI: 10.4172/2329-6887.1000171 Review Open Access Systematic Review of Tranexamic Acid Adverse Reactions Gioacchino Calapai2*, Sebastiano Gangemi1, Carmen Mannucci2, Paola Lucia Minciullo1, Marco Casciaro1, Fabrizio Calapai3, Maria Righi4 and Michele Navarra5 1Operative Unit of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Messina, Italy 2Department of Clinical and Experimental Medicine, University of Messina, Italy 3Centro Studi Pharma.Ca, Messina, Italy 4Department of Biomedical Sciences and Morphological and Functional Images, University of Messina, Italy 5Department of Drug Sciences and Health Products, University of Messina, Italy *Corresponding author: Gioacchino Calapai, Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria 5, 98125 Messina, Italy, Tel: +39 090 2213646; Fax: +39 090 221; E-mail: [email protected] Received date: July 06, 2015; Accepted date: July 14, 2015; Published date: July 20, 2015 Copyright: © 2015 Calapai G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Background Tranexamic acid is a synthetic lysine derivate that exerts its antifibrinolytic effect by reversible blocking lysine binding sites on plasminogen preventing fibrin degradation. It is widely used for haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. Aim The aim of our work was to review the literature regarding the best evidence on tranexamic adverse reactions and to describe them according to the apparatus involved.
    [Show full text]
  • Major Trauma Search Strategies Appendix
    National Clinical Guidelines Centre Draft Major Trauma Search strategies appendix Clinical guideline Appendices 10 June 2015 Draft Commissioned by the National Institute for Health and Care Excellence Guideline short title Contents Disclaimer Healthcare professionals are expected to take NICE clinical guidelines fully into account when exercising their clinical judgement. However, the guidance does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of each patient, in consultation with the patient and, where appropriate, their guardian or carer. Copyright National Clinical Guideline Centre, 2015. Funding National Institute for Health and Care Excellence National Clinical Guideline Centre, 2015. Guideline short title Contents Contents Appendix A: Literature search strategies ........................................................................................ 5 National Clinical Guideline Centre, 2015. 4 <ClickGuideline this shortfield ontitle the first page and insert document title / header text> Literature search strategies Appendix A: Literature search strategies A.1 Contents Introduction Search methodology Section A.2 Standard population search strategy A.2.1 Standard major trauma population A.2.2 Haemorrhage A.2.3 Chest trauma Section A.3 Study filter terms A.3.1 Systematic reviews (SR) A.3.2 Randomised controlled trials (RCT) A.3.3 Observational studies (OBS) A.3.4 Qualitative studies (QUAL) A.3.5 Diagnostic studies (DIAG) A.3.6 Health economic studies (HE) A.3.7 Quality
    [Show full text]
  • WO 2014/153004 Al 25 September 2014 (25.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2014/153004 Al 25 September 2014 (25.09.2014) P O P C T (51) International Patent Classification: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, A61L 27/58 (2006.01) A61L 27/52 (2006.01) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/US20 14/028622 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (22) International Filing Date: TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 14 March 2014 (14.03.2014) ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 61/785,477 14 March 2013 (14.03.2013) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (71) Applicant: MEDICUS BIOSCIENCES LLC [US/US]; MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 2528 Qume Dr., Unit #1, San Jose, CA 95 13 1 (US).
    [Show full text]
  • Severe Haemophilia a in a Preterm Girl With
    Berendt et al. Italian Journal of Pediatrics (2020) 46:125 https://doi.org/10.1186/s13052-020-00892-7 CASE REPORT Open Access Severe haemophilia a in a preterm girl with turner syndrome - a case report from the prenatal period to early infancy (part I) Agnieszka Berendt1* , Monika Wójtowicz-Marzec1, Barbara Wysokińska2 and Anna Kwaśniewska1 Abstract Background: Bleedings are more frequent in the population of preterm children than among those born at term, much less in older children. The reasons for such bleedings in preterms include plasma factor deficiencies, immaturity of small vessels in the germinal matrix region, prenatal hypoxia or sepsis. They affect the brain tissue, the gastrointestinal tract and the respiratory system, or are manifested by prolonged bleedings from injection sites. Haemophilia is a rare cause of haemorrhages in the neonatal period, and in the female population it is even seen as an extremely rare disorder. Its aetiology in girls is diverse: inheriting defective genes from their parents, skewed X inactivation or a single X chromosome. Case presentation: The article presents a case of a preterm girl born in the 28th week of pregnancy, who was diagnosed with severe haemophilia A stemming from the absence of the X chromosome. The girl’s father is healthy, but her mother’s brother suffers from haemophilia. On the second day of the child’s life, a prolonged bleeding from the injection site was observed. A coagulation profile revealed prolonged APTT which pointed to haemophilia A diagnosis. Moreover, a marked clinical dysmorphy, female sex and a negative family history on the father’s side led the treating team to extend the diagnostic procedures to encompass karyotype evaluation.
    [Show full text]
  • 3258 N:O 1179
    3258 N:o 1179 LIITE 1 BILAGA 1 LÄÄKELUETTELON AINEET ÄMNENA I LÄKEMEDELSFÖRTECKNINGEN Latinankielinen nimi Suomenkielinen nimi Ruotsinkielinen nimi Englanninkielinen nimi Latinskt namn Finskt namn Svenskt namn Engelskt namn Abacavirum Abakaviiri Abakavir Abacavir Abciximabum Absiksimabi Absiximab Abciximab Acamprosatum Akamprosaatti Acamprosat Acamprosate Acarbosum Akarboosi Akarbos Acarbose Acebutololum Asebutololi Acebutolol Acebutolol Aceclofenacum Aseklofenaakki Aceklofenak Aceclofenac Acediasulfonum natricum Asediasulfoninatrium Acediasulfonnatrium Acediasulfone sodium Acepromazinum Asepromatsiini Acepromazin Acepromazine Acetarsolum Asetarsoli Acetarsol Acetarsol Acetazolamidum Asetatsoliamidi Acetazolamid Acetazolamide Acetohexamidum Asetoheksamidi Acetohexamid Acetohexamide Acetophenazinum Asetofenatsiini Acetofenazin Acetophenazine Acetphenolisatinum Asetofenoli-isatiini Acetfenolisatin Acetphenolisatin Acetylcholini chloridum Asetyylikoliinikloridi Acetylkolinklorid Acetylcholine chloride Acetylcholinum Asetyylikoliini Acetylkolin Acetylcholini Acetylcysteinum Asetyylikysteiini Acetylcystein Acetylcysteine Acetyldigitoxinum Asetyylidigitoksiini Acetyldigitoxin Acetyldigitoxin Acetyldigoxinum Asetyylidigoksiini Acetyldigoxin Acetyldigoxin Acetylisovaleryltylosini Asetyyli-isovaleryyli- Acetylisovaleryl- Acetylisovaleryltylosine tartras tylosiinitartraatti tylosintartrat tartrate Aciclovirum Asikloviiri Aciklovir Aciclovir Acidum acetylsalicylicum Asetyylisalisyylihappo Acetylsalicylsyra Acetylsalicylic acid Acidum alendronicum
    [Show full text]
  • Farmaatsia- Terminoloogia Teine, Täiendatud Trükk
    Farmaatsia- terminoloogia Teine, täiendatud trükk Graanulid Suspensioon Lahus Emulsioon Pillid Pulber Salv Kreem Aerosool Plaaster Sprei Pastill Tampoon Oblaat Emulsioon Kontsentraat Silmageel Tablett Haavapulk Ninatilgad Kapsel Lakukivi Inhalaator Farmaatsia- terminoloogia Teine, täiendatud trükk Tartu 2019 Koostajad: Toivo Hinrikus, Karin Kogermann, Ott Laius, Signe Leito, Ain Raal, Andres Soosaar, Triin Teppor, Daisy Volmer Keeletoimetaja: Tiina Kuusk Kirjastanud: Ravimiamet Nooruse 1, 50411 Tartu Telefon: +372 737 4140 Faks: +372 737 4142 E-post: [email protected] Esimene trükk 2010 Teine, täiendatud trükk 2019 Raamat on leitav Ravimiameti veebilehelt: www.ravimiamet.ee/farmaatsiaterminoloogia Väljaande refereerimisel või tsiteerimisel palume viidata allikale. ISBN 978-9949-9697-3-9 Sisukord Farmaatsiaterminoloogia Eestis..........................................................................................5 Üldised farmaatsiaalased terminid ...................................................................................10 Euroopa farmakopöa ......................................................................................................... 21 Euroopa farmakopöa sõnastik ..........................................................................................24 Standardterminid ..............................................................................................................29 Ravimvormid .....................................................................................................................29
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Medicines Formulary
    MEDICINES FORMULARY Medicines formulary between MCHFT and primary care as agreed by the Joint Medicines Management Group Welcome to the MCHFT Medicines Formulary. The formulary includes medicines that have been approved by the Joint Medicines Management Group (JMMG) for prescribing within the trust. The purpose of the formulary is to ensure prescribing is evidence based and cost effective. All prescribing within the trust (i.e. inpatient, outpatient and FP10HNC prescribing) must comply with the formulary. This will be monitored on a regular basis. Some drugs may appear in more than one section. Information on prescribing in primary care is available via the Medicines Management Team website: http://www.centralandeasterncheshiremmt.nhs.uk This is a good point of reference to confirm the continuation of medicines in primary care after initiation at MCHFT. Please note medicines contained in the primary care formulary are not automatically formulary at MCHFT. The formulary is arranged in sections corresponding to those in the British National Formulary (BNF) as below; INTRODUCTION .......................................................................................................................................... 2 UPDATES TO THE FORMULARY (LAST UPDATE APRIL 2021) .............................................................. 4 1. GASTRO-INTESTINAL SYSTEM ............................................................................................................. 9 2. CARDIOVASCULAR SYSTEM .............................................................................................................
    [Show full text]